Navigation path

Left navigation

Additional tools

Other available languages: FR DE


Brussels, 3 rd February 2010

Mergers: Commission approves acquisition of IMS Health by TPG

The European Commission has cleared under the EU Merger Regulation the proposed acquisition of IMS Health Incorporated by two investment funds - TPG Partners V and TPG Partners VI - belonging to the TPG investment firm, all of the US. IMS is the leading provider of market research services (MRS) in the health sector. After examining the operation, the Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.

TPG Partners V, L.P. and TPG Partners VI, L.P. are private equity funds, which invest in a variety of companies through acquisitions and corporate restructurings .

IMS Health provides market research information and consulting services to customers in the pharmaceutical industry.

There are no horizontal overlaps between the parties' activities. However, the proposed operation leads to a vertical relationship between the supply of health-related market research services by IMS, and the development and marketing of finished pharmaceuticals by Axcan Pharma, a Canadian pharmaceutical producer controlled by TPG. The Commission examined the effects of the proposed transaction and found that IMS Health would have no incentive to restrict access to its market research services.

More information on the case will be available at:

Side Bar